Imitation may be the highest form of flattery, but that wasn’t helping Hims & Hers Health stock on Tuesday. In response to high demand for its weight-loss treatment, Eli Lilly announced that Zepbound 2.5 mg and 5 mg single-dose vials—priced at a 50% or more discount compared with other weight-loss drugs—will be available for self-pay for patients with an on-label prescription. The news sent shares of Hims & Hers—the company sells direct-to-consumer generic prescription medicines, including weight-loss drugs—down 7.5% on Tuesday.